Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Steven Warach MD, PhD

Steven J. Warach MD, PhD

Professor of Neurology, University of Texas Southwestern Medical Center; Director of Cerebrovascular Medicine, Seton Healthcare Family, Austin, Texas

Steven Warach, MD, PhD. Dr. Warach graduated from Michigan State University with a doctorate in neuroscience and psychology. He received his medical degree and neurology residency training at Harvard Medical School, before joining the Harvard Medical School faculty in 1993, as Chief of the Division of Cerebrovascular Diseases at Beth Israel Hospital. In 1999, he was recruited by the National Institutes of Neurological Disorders and Stroke as Senior Investigator and Chief of the Section of Stroke Diagnostics and Therapeutics, a translational clinical research program in acute stroke that established the first stroke centers in Washington DC and Suburban Maryland. In 2011, he was recruited by University of Texas Southwestern Medical Center and the Seton Healthcare Family to serve as Professor and founding Executive Director of the Seton/UT Southwestern Clinical Research Institute of Austin and the Director of Cerebrovascular Medicine of the Seton Healthcare Family. Dr. Warach’s research is internationally recognized as introducing advanced MRI methods for more accurate diagnosis of stroke into clinical practice and for pioneering patient-specific, imaging-defined therapeutic targets in the development of new stroke therapies.